Mutations in the genes encoding embryonic and neonatal myosin (MYH3 and MYH8) have been associated with distal arthrogryposes 1 .
MYH2 mutations cause dominant and recessive disease. Dominant mutations were first described in a family with congenital joint contractures, which largely resolve with age, and external ophthalmoplegia. Some patients later develop mild to moderate, predominantly proximal limb weakness 3, 4 . Rimmed vacuoles, intranuclear and cytoplasmic inclusions in the muscle biopsies initially led to the entity being labelled as inclusion body myopathy 3 (IBM3) 3 . Recently, a patient was described with severe bulbar and respiratory involvement from birth, external ophthalmoplegia and a "waddling-steppage gait", who had a de novo heterozygous c.5609T>C (reported as c.5737T>C), p.(Leu1870Pro) mutation of MYH2 5 . Recessive patients with homozygous or compound heterozygous mutations have severe external ophthalmoplegia and mild limb weakness. 6, 7, 8 Thus, external ophthalmoplegia is a constant clinical hallmark of MYH2 myopathies. Two other patients with only myalgia or mild proximal weakness had heterozygous variants in MYH2 9 , though these variants, from their frequency in public databases, are likely polymorphisms.
MYH7 mutations are associated with three major allelic diseases: cardiomyopathy, myosin storage myopathy and Laing distal myopathy 1 . Cardiomyopathy most frequently results from mutations involving the MyHC I globular head domain 1 , whereas myosin storage myopathy, manifesting predominantly as a scapuloperoneal syndrome, results from mutations in the distal tail of MyHC I 1, 2 . Laing distal myopathy results most commonly from mutations in the mid region of the tail, although mutations in the distal tail and in the head domain have also been described 2 .
The genetic basis of oculopharyngodistal myopathy (OMIM #164310) (OPDM) is unknown, but it shows both autosomal dominant and recessive inheritance. The main features are ophthalmoplegia, ptosis, bulbar dysfunction and distal limb weakness with onset spanning from 7 to 50 years. 10, 11 Muscle biopsy features include rimmed and autophagic vacuoles 10 and 16-18 nm cytoplasmic filaments in patients with recessive disease. 12 We report a patient with ophthalmoplegia, dysphagia and limb weakness, with significant involvement of distal muscles from onset, initially diagnosed as OPDM, and harbouring a mutation in MYH2. He slowly deteriorated, developing dysphagia and respiratory involvement with a moderate restrictive ventilatory defect.
His forced vital capacity was 57% predicted, necessitating intermittent CPAP. He had severe contractures of his ankles, but was able to walk with full leg calipers until age 50.
Electromyography performed at age 25 showed normal nerve conduction studies but a widespread myopathic pattern.
A muscle MRI performed at age 58 showed extensive fat replacement. The deltoids and anterior compartment of the legs were relatively spared. Medial heads of gastrocnemious were less affected than lateral heads (Fig. 1 ).
His serum creatine kinase (CK) ranged between 153 and 806. ECG and echocardiogram performed at age 44 were both normal. Both parents had normal CK levels.
Histology
Five muscle biopsies were performed at age 20 (right biceps and right vastus lateralis), 32 (right vastus lateralis) and 46 (left vastus lateralis and left deltoid).
The biopsies were stained with haematoxylin and eosin, ATPase pH 9.4, 4.6 and 4.3, metabolic stains and a picro-Mallory's stain. Slow (Milipore, clone MAB1628) and fast myosin (Sigma, clone MY-32) immunohistochemistry (IHC) was performed on paraffin embedded tissue. IHC was performed for dystrophin (Rod, C-terminal and N-terminal domains), α, β, ϒ, and δ sarcoglycans, α and β dystroglycan, merosin, dysferlin, caveolin3 and spectrin. Targeted capture and next generation sequencing (NGS) of 277 known and candidate neuromuscular disease genes (manuscript in preparation) was then performed. Bioinformatic analysis of the sequencing data used the previously published in-house pipeline 14 . Confirming the presence of the MYH2 variant and screening of relatives was done by Sanger sequencing.
Genetic analysis
RNA was extracted from the patient's vastus lateralis biopsy taken at 20 years of age and controls using RNeasy Fibrous
Tissue Mini Kit (Qiagen). Synthesis of first strand cDNA was performed using SuperScript® III First-Strand Synthesis (Invitrogen). To analyse the relative expression of MYH isoform transcripts, we performed a multiplex PCR and fragment analysis as described. 13 MYH2 cDNA exons 36 to 40 were sequenced using primers specific for MYH2 (available on request).
RESULTS

Histology
Common features in all the biopsies were increased variability in fibre size, atrophic and hypertrophic fibres ranging from 20 to 250 µm in diameter, internal nuclei (up to 15%) and endomysial fibrosis. Dystrophic features were present, being more prominent later in the disease. Deltoid was relatively spared compared to vastus lateralis (Fig. 2) .
Oxidative enzyme stains demonstrated abundant lobulated fibres, and core-like structures. In some areas, all fibres were lobulated except for scattered hypertrophic fibres which showed central cores ( Fig. 2E and 2G ). Electron microscopy confirmed these findings ( Fig. 1M-P) . No rimmed vacuoles were seen. All fibres were Type 1, except for a few scattered small Type 2 fibres. This fibre type distribution was found in deltoid ( Fig. 2I-L ) and vastus lateralis (not shown).
Immunohistochemical staining showed normal labelling of all other proteins examined (not shown).
Genetic work-up NGS for the patient's DNA covered 92.4% of targets to >20-fold, with 247-fold average coverage. After filtering variants in the EVS (http://evs.gs.washington.edu/EVS/) or 1000 genomes databases (www.1000genomes.org) with frequency >1%, a number of heterozygous variants in genes associated with autosomal recessive diseases, but no homozygous or compound heterozygous variants, were identified. Two variants were identified in genes associated with dominant diseases. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 2) A heterozygous change in exon 39 of MYH2 (NM_017534.5): c.5630T>C p(.Leu1877Pro). This variant was not present in the EVS or 1000 genomes databases. The putative amino-acid change involved a highly conserved amino acid (Fig. 3B) , and would insert a proline residue in the coiled-coil tail of MyHC IIa. This was predicted to be deleterious by all in-silico predictors used (Mutation Taster, PolyPhen2 and SIFT). The variation was confirmed in the proband by Sanger sequencing, but was not present in peripheral blood DNA of either of the parents, or the 2 unaffected siblings for whom DNA samples were available. Sample identity was confirmed, suggesting the proband had a de novo mutation, or one parent had gonadal mosaicism for the mutation.
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To exclude the possibility of a second mutation causing a null allele, we sequenced exons 36 to 40 on cDNA showing that both the wild type and the mutant allele were expressed, although the mutant seemed present in a lower amount, as inferred from the smaller peak corresponding to the mutant allele, seen in the chromatogram (Fig. 3A) .
To further investigate the effect of the mutation, we quantified the MYH isoform transcripts in the patient muscle. This showed almost complete absence of both MYH1 and MYH2 transcripts (Fig 3C) , as expected from the very few Type II fibres seen in the biopsies. The muscle pathology in our patient and that of D'Amico et al 5 , with Type 1 uniformity apart from a few scattered small Type 2 fibres, is almost identical. This has also been described in patients with recessive mutations 7, 8 . How dominant missense mutations to proline in the MyHC IIa tail lead to loss of both Type 2a and 2b fibres is currently unknown. The p.(Leu1877Pro) variant involves the first amino acid of the "assembly competence domain" of MyHC IIa (Fig. 3) which is a 29-residue motif essential for self-assembly of myosin molecules 15 . The mutations in our patient and that of D'Amico et al lobulated fibres has not been described previously in patients with MYH2 mutations. Lobulated fibres are regarded as nonspecific, of uncertain significance and their pathophysiology is unknown but it is unusual to find them in such high proportion 16 .
In our patient, changes were more prominent in vastus lateralis than in deltoid as seen clinically, pathologically and radiologically. However, the anterior compartments of lower legs were severely affected clinically, but the MRI showed relative sparing. This also seems to be the case in the patient of D'Amico et al 5 , where a steppage gait is described at age 12 but the MRI shows sparing of tibialis anterior. A common radiologic pattern can thus be established with D'Amico et al's patient, though in our patient the MRI was performed much later in the disease progress. The pathobiological basis of the preferential susceptibility or sparing of muscles in MYH2 myopathy, as in other genetic muscle diseases, is unknown, but may involve the relative expression of other genes or protein isoforms in different muscles.
Our patient was initially diagnosed with OPDM since the distribution of weakness, including significant distal weakness at onset, ophthalmoplegia and dysphagia, suggested this diagnosis. Significant distal limb weakness is not generally a feature in patients with MyHC IIa myopathies [4] [5] [6] [7] [8] , but may be inferred for the patient described by D'Amico et al from the "waddling-steppage gait" clinical description 5 . Equally, some OPDM patients may have only proximal limb weakness or no limb weakness at all 10 . Rimmed vacuoles and tubulo-filamentous inclusions have been reported in both diseases 3, 12 .
Dystrophic features may occur in severely affected muscles of MyHC IIa myopathy but have not been reported in OPDM.
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